Education
About Us
Working with TipRanks
Follow Us
PPH - AI Analysis
Top Page
VanEck Pharmaceutical ETF (PPH)
Rating:72Outperform
Price Target:
$102.00
Positive Factors
Strong Top Holdings
Several key holdings, such as Novartis, McKesson, and Johnson & Johnson, have delivered strong year-to-date performance, supporting the ETF's overall returns.
Low Expense Ratio
The ETF charges a competitive expense ratio, making it cost-effective compared to many other funds.
Focused Sector Strength
The ETF is heavily concentrated in the health care sector, which has historically shown resilience during economic uncertainty.
Negative Factors
Over-Concentration in Health Care
With nearly 100% exposure to the health care sector, the ETF is vulnerable to sector-specific risks.
Weak Performance from Some Holdings
Several top holdings, including Novo Nordisk and Pfizer, have underperformed year-to-date, which could drag on overall returns.
Limited Geographic Diversification
The ETF is almost entirely focused on U.S. companies, offering little exposure to international markets.
PPH vs. SPDR S&P 500 ETF (SPY)
AUM1.26B
RegionGlobal
Expense Ratio0.36%
Beta0.47
IssuerVanEck
Inception DateDec 20, 2011
Dividend Yield2.09%
Asset ClassEquity
Index TrackedMVIS US Listed Pharmaceutical 25
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume347,938
30 Day Avg. Volume530,812
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
103.92Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering26
PPH Summary
The VanEck Pharmaceutical ETF (PPH) is an investment fund that focuses on the pharmaceutical sector, tracking the MVIS US Listed Pharmaceutical 25 Index. It includes major companies like Eli Lilly and Novartis, which are leaders in developing and producing medications and therapies. This ETF is ideal for investors looking to benefit from the growth of the healthcare industry, driven by aging populations and increasing demand for innovative treatments. However, new investors should be aware that the ETF’s performance is closely tied to the pharmaceutical industry, which can be affected by regulatory changes and competition.
How much will it cost me?The VanEck Pharmaceutical ETF (PPH) has an expense ratio of 0.36%, which means you’ll pay $3.60 per year for every $1,000 invested. This is slightly higher than the average for passively managed ETFs because it focuses on a specialized sector, the pharmaceutical industry, which may require more research and management to track effectively.
What would affect this ETF?The VanEck Pharmaceutical ETF (PPH) could benefit from trends like aging populations, increased healthcare spending, and advancements in medical research, which drive demand for innovative treatments and medications. However, it may face challenges from regulatory changes, patent expirations, or pricing pressures in the pharmaceutical industry, which could impact the profitability of its top holdings like Eli Lilly, Novartis, and Pfizer.
PPH Top 10 Holdings
The VanEck Pharmaceutical ETF (PPH) is leaning heavily on Eli Lilly, which has shown steady growth, and Novartis, a rising star with strong financials and shareholder-friendly moves. Novo Nordisk, however, is lagging, weighed down by challenges in the U.S. market and declining cash flow. McKesson has been a bright spot, delivering solid revenue growth, while Pfizer’s performance has been mixed, with short-term weakness offset by its attractive dividend yield. With nearly all holdings in the healthcare sector and global exposure, this ETF is a concentrated bet on the evolving pharmaceutical industry.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 21.00% | $260.75M | $781.25B | -7.72% | 70 Outperform | |
| Novartis | 9.64% | $119.67M | $249.53B | 11.68% | 78 Outperform | |
| Merck & Company | 7.56% | $93.82M | $218.53B | -15.57% | 76 Outperform | |
| Novo Nordisk | 7.19% | $89.31M | $237.08B | -52.93% | 73 Outperform | |
| McKesson | 4.91% | $60.92M | $99.72B | 59.43% | 74 Outperform | |
| Pfizer | 4.84% | $60.06M | $140.77B | -14.17% | 78 Outperform | |
| Sanofi | 4.73% | $58.73M | $126.22B | -5.43% | 76 Outperform | |
| Johnson & Johnson | 4.68% | $58.09M | $458.73B | 17.76% | 78 Outperform | |
| AbbVie | 4.65% | $57.78M | $402.76B | 20.22% | 64 Neutral | |
| GlaxoSmithKline | 4.61% | $57.26M | $86.97B | 15.63% | 72 Outperform |
PPH Technical Analysis
Neutral
―
Price Trends
90.02
Positive
88.40
Positive
87.75
Positive
Market Momentum
0.66
Positive
50.40
Neutral
67.40
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PPH, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 92.65, equal to the 50-day MA of 90.02, and equal to the 200-day MA of 87.75, indicating a neutral trend. The MACD of 0.66 indicates Positive momentum. The RSI at 50.40 is Neutral, neither overbought nor oversold. The STOCH value of 67.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PPH.
PPH Peer Comparison
Comparison Results
Performance Comparison
PPH
VanEck Pharmaceutical ETF
91.43
1.11
1.23%
IGF
iShares Global Infrastructure ETF
―
―
―
ARKK
Ark Innovation Etf
―
―
―
BAI
iShares A.I. Innovation and Tech Active ETF
―
―
―
IXN
iShares Global Tech ETF
―
―
―
IXJ
iShares Global Healthcare ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents